Improving Glioblastoma Therapeutic Outcomes via Doxorubicin-Loaded Nanomicelles Modified with Borneol.

Borneol (BO) was firstly conjugated with DSPE-PEG2000-COOH to synthesize a novel carrier DSPE-PEG2000-BO to enhance the delivery of doxorubicin (DOX) into brain for glioblastoma therapy. BO-modified nanomicelles loading doxorubicin (DOX BO-PMs) were prepared using DSPE-PEG2000-BO and investigated thoroughly. DOX BO-PMs significantly enhanced the transport efficiency of DOX across blood-brain barrier (BBB) and also showed a quick accumulation in brain. More importantly, DOX BO-PMs exhibited the significant inhibition effect on the tumor growth and metastasis in the mouse glioblastoma model. DOX BO-PMs can improve the therapeutic outcomes of glioblastoma and become a promising nanodrug candidate for the application of doxorubicin in the field of glioblastoma therapy.